Sermorelin for adult longevity or wellness is off-label. It is FDA-approved only for growth hormone deficiency in children.
Risks and monitoring
- Risks include fluid retention, joint/muscle pain, carpal tunnel, and insulin resistance.
- IGF-1 elevation carries theoretical cancer promotion risk — must be disclosed and monitored.
- Baseline and follow-up labs (e.g., IGF-1) may be required at 3–6 month intervals.
- Contraindicated in active malignancy, diabetic retinopathy, and active carpal tunnel.